Drugs, Addiction, and the Brain

Drugs, Addiction, and the Brain

Volumn , Issue , 2014, Pages 1-342

  Koob, George F ^a   Arends, Michael A ^a   Le Moal, Michel ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84941703208     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/C2010-0-68399-4     Document Type: Book

References (169)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2013, American Psychiatric Publishing, Washington DC. fifth ed.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Press, Washington DC. fourth ed.
3. Losing Control: How and Why People Fail at Self-Regulation 1994, Academic Press, San Diego. R.F. Baumeister, T.F. Heatherton, D.M. Tice (Eds.).
4. Colpaert F.C. System theory of pain and of opiate analgesia: no tolerance to opiates. Pharmacol. Rev. 1996, 48:355-402.
5. Himmelsbach C.K. Can the euphoric, analgetic, and physical dependence effects of drugs be separated? IV. With reference to physical dependence. Fed. Proc. 1943, 2:201-203.
6. Kandel D.B. Stages in adolescent involvement in drug use. Science 1975, 190:912-914.
7. Khantzian E.J. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv. Rev. Psychiatry. 1997, 4:231-244.
8. Koob G.F., Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997, 278:52-58.
9. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001, 24:97-129.
10. McLellan A.T., Lewis D.C., O'Brien C.P., Kleber H.D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. J. Am. Med. Assoc. 2000, 284:1689-1695.
11. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 1993, 18:247-291.
12. Solomon R.L., Corbit J.D. An opponent-process theory of motivation: 1. Temporal dynamics of affect. Psychol. Rev. 1974, 81:119-145.
13. Solomon R.L. The opponent-process theory of acquired motivation: the costs of pleasure and the benefits of pain. Am. Psychol. 1980, 35:691-712.
14. Tyndale R.F., Sellers E.M. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug. Metab. Dispos. 2001, 29:548-552.
15. Vanderschuren L.J., Kalivas P.W. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology 2000, 151:99-120.
16. World Health Organization International Statistical Classification of Diseases and Related Health Problems, 10th revision 1992, World Health Organization, Geneva.
17. Alheid G.F., De Olmos J.S., Beltramino C.A. Amygdala and extended amygdala. The Rat Nervos System 1995, 495-578. Academic Press, San Diego. second ed. G. Paxinos (Ed.).
18. Belin D., Jonkman S., Dickinson A., Robbins T.W., Everitt B.J. Parallel and interactive learning processes within the basal ganglia: relevance for the understanding of addiction. Behav. Brain. Res. 2009, 199:89-102.
19. Clarke L.E., Barres B.A. Emerging roles of astrocytes in neural circuit development. Nat. Rev. Neurosci. 2013, 14:311-321. [erratum: 2013, 14: 451].
20. Kalivas P.W. The glutamate homeostasis hypothesis of addiction. Nat. Rev. Neurosci. 2009, 10:561-572.
21. Kettenmann H., Kirchhoff F., Verkhratsky A. Microglia: new roles for the synaptic stripper. Neuron 2013, 77:10-18.
22. Lüscher C., Malenka R.C. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 2011, 69:650-663.
23. Robbins T.W. Relationship between reward-enhancing and stereotypical effects of psychomotor stimulant drugs. Nature 1976, 264:57-59.
24. Schultz W., Dayan P., Montague P.R. A neural substrate of prediction and reward. Science 1997, 275:1593-1599.
25. Schultz W. Behavioral theories and the neurophysiology of reward. Annu. Rev. Psychol. 2006, 57:87-115.
26. Wolf M.E., Ferrario C.R. AMPA receptor plasticity in the nucleus accumbens after repeated exposure to cocaine. Neurosci. Biobehav. Rev. 2010, 35:185-211.
27. Andrews J.S., Broekkamp C.L.E. Procedures to identify anxiolytic or anxiogenic agents. Behavioral Neuroscience: A Practical Approach 1993, vol. 2:37-54. IRL Press, Oxford. A. Sahgal (Ed.).
28. Baker T.B., Cannon D.S. Potentiation of ethanol withdrawal by prior dependence. Psychopharmacology 1979, 60:105-110.
29. Becker H.C. Positive relationship between the number of prior ethanol withdrawal episodes and the severity of subsequent withdrawal seizures. Psychopharmacology 1994, 116:26-32.
30. Becker H.C., Hale R.L. Ethanol-induced locomotor stimulation in C57BL/6 mice following RO15-4513 administration. Psychopharmacology 1989, 99:333-336.
31. Belin D., Mar A.C., Dalley J.W., Robbins T.W., Everitt B.J. High impulsivity predicts the switch to compulsive cocaine-taking. Science 2008, 320:1352-1355.
32. Bindra D. A Theory of Intelligent Behavior 1976, Wiley, New York.
33. Branchey M., Rauscher G., Kissin B. Modifications in the response to alcohol following the establishment of physical dependence. Psychopharmacologia 1971, 22:314-322.
34. Caine S.B., Lintz R., Koob G.F. Intravenous drug self-administration techniques in animals. Behavioral Neuroscience: A Practical Approach 1993, vol. 2:117-143. IRL Press, Oxford. A. Sahgal (Ed.).
35. Ciccocippo R., Angeletti S., Weiss F. Long-lasting resistance to extinction of response reinstatement induced by ethanol-related stimuli: role of genetic ethanol preference. Alcohol. Clin. Exp. Res. 2001, 25:1414-1419.
36. Crombag H.S., Bossert J.M., Koya E., Shaham Y., Context-induced relapse to drug seeking: a review. Philos. Trans. R. Soc. London B Biol. Sci. 2002, 363:3233-3243.
37. Deroche-Gamonet V., Belin D., Piazza P.V. Evidence for addiction-like behavior in the rat. Science 2004, 305:1014-1017.
38. Ebel R.M. Must all tests be valid?. Am. Psychol 1961, 16:640-647.
39. Erb S., Shaham Y., Stewart J. Stress reinstates cocaine-seeking behavior after prolonged extinction and a drug-free period. Psychopharmacology 1996, 128:408-412.
40. Gauvin D.V., Holloway F.A. Cue dimensionality in the three-choice pentylenetetrazole-saline-chlordiazepoxide discrimination task. Behav. Pharmacol. 1991, 2:417-428.
41. Gellert V.F., Holtzman S.G. Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J. Pharmacol. Exp. Ther. 1978, 205:536-546.
42. Geyer M.A., Markou A. The role of preclinical models in the development of psychotropic drugs. Neuropsychopharmacology: The Fifth Generation of Progress 2002, 445-455. Lippincott Williams and Wilkins, New York. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds.).
43. Hand T.H., Koob G.F., Stinus L., Le Moal M. Aversive properties of opiate receptor blockade: evidence for exclusively central mediation in naive and morphine-dependent rats. Brain. Res. 1988, 474:364-368.
44. Hebb D.O. Organization of Behavior: A Neuropsychological Theory 1949, Wiley, New York.
45. Holtzman S.G. Discriminative stimulus effects of drugs: relationship to potential for abuse. series title: Modern Methods in Pharmacology 1990, vol. 6:193-210. Wiley, New York. M.W. Adler, A. Cowan (Eds.).
46. Katner S.N., Magalong J.G., Weiss F. Reinstatement of alcohol-seeking behavior by drug-associated discriminative stimuli after prolonged extinction in the rat. Neuropsychopharmacolcogy 1999, 20:471-479.
47. Katz J.L., Higgins S.T. The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology 2003, 168:21-30. [erratum: 168: 244].
48. Kling J.W., Riggs L.A. Woodworth and Schlosberg's Experimental Psychology 1971, Holt, Rinehart and Winston, New York. third ed.
49. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacol. Rev. 2010, 35:217-238. [erratum: (35) 1051].
50. Koob G.F. New dimensions in human laboratory models of addiction. Addict. Biol. 2009, 14:1-8.
51. Kornetsky C., Bain G. Brain-stimulation reward: a model for drug-induced euphoria. series title: Modern Methods in Pharmacology 1990, vol. 6:211-231. Wiley-Liss, New York. M.W. Adler, A. Cowan (Eds.).
52. Kornetsky C., Esposito R.U. Euphorigenic drugs: effects on the reward pathways of the brain. Fed. Proc. 1979, 38:2473-2476.
53. Lu L., Grimm J.W., Hope B.T., Shaham Y. Incubation of cocaine craving after withdrawal: a review of preclinical data. Neuropharmacology 2004, 47(suppl. 1):214-226.
54. Macey D.J., Schulteis G., Heinrichs S.C., Koob G.F. Time-dependent quantifiable withdrawal from ethanol in the rat: effect of method of dependence induction. Alcohol 1996, 13:163-170.
55. Malin D.H., Lake J.R., Newlin-Maultsby P., Roberts L.K., Lanier J.G., Carter V.A., Cunningham J.S., Wilson O.B. Rodent model of nicotine abstinence syndrome. Pharmacol. Biochem. Behav. 1992, 43:779-784.
56. Markou A., Koob G.F. Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol. Behav 1992, 51:111-119.
57. McKinney W.T. Models of Mental Disorders: A New Comparative Psychiatry 1988, Plenum, New York.
58. Olds J., Milner P. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J. Comp. Physiol. Psychol. 1954, 47:419-427.
59. Rhodes J.S., Best K., Belknap J.K., Finn D.A., Crabbe J.C. Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice. Physiol. Behav. 2005, 84:53-63.
60. Richter C.P. Animal behavior and internal drives. Q. Rev. Biol. 1927, 2:307-343.
61. Roberts A.J., Heyser C.J., Cole M., Griffin P., Koob G.F. Excessive ethanol drinking following a history of dependence: animal model of allostasis. Neuropsychopharmacology 2000, 22:581-594.
62. See R.E., Grimm J.W., Kruzich P.J., Rustay N. The importance of a compound stimulus in conditioned drug seeking behavior following one week of extinction from self-administered cocaine in rats. Drug. Alcohol. Depend. 1999, 57:41-49.
63. Shaham Y., Shalev U., Lu L., de Wit H., Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 2003, 168:3-20.
64. Shippenberg T.S., Koob G.F. Recent advances in animal models of drug addiction and alcoholism. Neuropsychopharmacology: The Fifth Generation of Progress 2002, 1381-1397. Lippincott Williams and Wilkins, Philadelphia. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds.).
65. Simms J.A., Steensland P., Medina B., Abernathy K.E., Chandler L.J., Wise R., Bartlett S.E. Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcohol. Clin. Exp. Res. 2008, 32:1816-1823.
66. Stellar J.R., Stellar E. The Neurobiology of Motivation and Reward 1985, Springer-Verlag, New York.
67. Stewart J., de Wit H. Reinstatement of drug taking behavior as a method of assessing incentive motivational properties of drugs. Methods of Assessing the Reinforcing Properties of Abused Drugs 1987, 211-227. Springer-Verlag, New York. M.A. Bozarth (Ed.).
68. Wikler A. Dynamics of drug dependence: implications of a conditioning theory for research and treatment. Arch. Gen. Psychiatry. 1973, 28:611-616.
69. Wise R.A. Voluntary ethanol intake in rats following exposure to ethanol on various schedules. Psychopharmacologia 1973, 29:203-210.
70. Yahyavi-Firouz-Abadi N., See R.E. Anti-relapse medications: preclinical models for drug addiction treatment. Pharmacol. Ther. 2009, 124:235-247.
71. Aston-Jones G., Harris G.C. Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology 2004, 47(suppl 1):167-179.
72. Belin D., Everitt B.J. Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum. Neuron 2008, 57:432-441.
73. Di Chiara G. Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav. Brain. Res. 2002, 137:75-114.
74. Everitt B.J., Wolf M.E. Psychomotor stimulant addiction: a neural systems perspective. J. Neurosci. 2002, 22:3312-3320. [erratum: 22(16): 1a].
75. Goldstein R.Z., Volkow N.D. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry. 2002, 159:1642-1652.
76. Grueter B.A., Rothwell P.E., Malenka R.C. Integrating synaptic plasticity and striatal circuit function in addiction. Curr. Opin. Neurobiol. 2012, 22:545-551.
77. Jentsch J.D., Taylor J.R. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology 1999, 146:373-390.
78. Kalivas P.W., McFarland K. Brain circuitry and the reinstatement of cocaine seeking behavior. Psychopharmacology 2003, 168:44-56.
79. Koob G.F. Drugs of abuse: anatomy, pharmacology, and function of reward pathways. Trends. Pharmacol. Sci. 1992, 13:177-184.
80. Koob G.F., Kreek M.J. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am. J. Psychiatry. 2007, 164:1149-1159.
81. Koob G.F., Le Moal M. Neurobiology of Addiction 2006, Academic Press, London.
82. Lyon M., Robbins T.W. The action of central nervous system stimulant drugs: a general theory concerning amphetamine effects. Current Developments in Psychopharmacology 1975, vol. 2:79-163. Spectrum Publications, New York. W.B. Essman, L. Valzelli (Eds.).
83. Nestler E.J. Is there a common molecular pathway for addiction?. Nat. Neurosci. 2005, 8:1445-1449.
84. Piazza P.V., Le Moal M. Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Annu. Rev. Pharmacol. Toxicol. 1996, 36:359-378.
85. Rylander G. Stereotype behavior in man following amphetamine abuse. series title: International Congress Series 1971, vol. 220:28-31. Excerpta Medica, Amsterdam. S.B.C. Baker (Ed.).
86. See R.E., Fuchs R.A., Ledford C.C., McLaughlin J. Drug addiction, relapse, and the amygdala. series title: Annals of the New York Academy of Sciences 2003, vol. 985:294-307. New York Academy of Sciences, New York. P. Shinnick-Gallagher, A. Pitkanen, A. Shekhar, L. Cahill (Eds.).
87. Shaham Y., Shalev U., Lu L., de Wit H., Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 2003, 168:3-20.
88. Siegel R.K. Cocaine smoking. J. Psychoactive Drugs 1982, 14:271-359.
89. Thomas M.J., Malenka R.C. Synaptic plasticity in the mesolimbic dopamine system. Trans. R. Soc. Lond. B Biol. Sci. 2003, 358:815-819.
90. Volkow N.D., Fowler J.S., Wang G.J. The addicted human brain: insights from imaging studies. J. Clin. Invest. 2003, 111:1444-1451.
91. Volkow N.D., Fowler J.S., Wang G.J., Baler R., Telang F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 2009, 56(suppl 1):3-8.
92. Zhang J., Berridge K.C., Tindell A.J., Smith K.S., Aldridge J.W. A neural computational model of incentive salience. PLoS Comput. Biol. 2009, 5:e1000437.
93. Chen S.A., O'Dell L., Hoefer M., Greenwell T.N., Zorrilla E.P., Koob G.F. Unlimited access to heroin self-administration: independent motivational markers of opiate dependence. Neuropsychopharmacology 2006, 3(1):2692-2707. [corrigedum: 3(1), 2802].
94. Gutstein H.B., Akil H. Opioid analgesics. Goodman and Gilman's The Pharmacological Basis of Therapeutics 2001, 569-619. McGraw-Hill, New York. tenth ed. J.G. Hardman, L.E. Limbird, A. Goodman-Gilman (Eds.).
95. Himmelsbach C.K. Clinical studies of drug addiction: physical dependence, withdrawal and recovery. Arch. Intern. Med. 1942, 69:766-772.
96. Jansson L.M., Velez M., Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J. Opioid Manag. 2009, 5:47-55.
97. Nestler E.J. Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci. 2001, 2:119-128.
98. Shurman J., Koob G.F., Gutstein H.B. Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain. Panminerva. Med. 2010, 11:1092-1098.
99. Simonnet G., Rivat C. Opioid-induced hyperalgesia: abnormal or normal pain?. Neuroreport 2003, 14:1-7.
100. Cottino A. International Handbook on Alcohol and Culture 1995, pp. 156-167. Italy., Greenwood Press, Westport, CT. D.B. Heath (Ed.).
101. Crabbe J.C., Phillips T.J., Harris R.A., Arends M.A., Koob G.F. Alcohol-related genes: contributions from studies with genetically engineered mice. Add. Biol. 2006, 11:195-269.
102. Harris R.A., Trudell J.R., Mihic S.J. Ethanol's molecular targets. Sci. Signal. 2008, 1(28). re7.
103. Kalant H. Research on tolerance: what can we learn from history?. Alcohol. Clin. Exp. Res. 1998, 22:67-76.
104. Koob G.F. Alcoholism: allostasis and beyond. Alcohol. Clin. Exp. Res. 2003, (27):232-243.
105. Koob G.F. A role for brain stress systems in addiction. Neuron 2008, 59:11-34.
106. Koob G.F., Lloyd G.K., Mason B.J. Development of pharmacotherapies for drug addiction: a Rosetta Stone approach. Nat. Rev. Drug Discov. 2009, 8:500-515.
107. Liu X., Weiss F. Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J. Neurosci. 2002, 22:7856-7861.
108. Movva R., Figueredo V.M. Alcohol and the heart: to abstain or not to abstain?. Int. J. Cardiol 2013, 164:267-276.
109. Murphy J.M., Stewart R.B., Bell R.L., Badia-Elder N.E., Carr L.G., McBride W.J., Lumeng L., Li T.K. Phenotypic and genotypic characterization of the Indiana University rat lines selectively bred for high and low alcohol preference. Behavior Genetics 2002, 32:363-388.
110. Nahoum-Grappe V. International Handbook on Alcohol and Culture 1995, 75-87. France, Greenwood Press, Westport, CT. D.B. Heath (Ed.).
111. Nyberg K., Allebeck P. International Handbook on Alcohol and Culture 1995, 156-167. Sweden, Greenwood Press, Westport, CT. D.B. Heath (Ed.).
112. Palmer R.H., McGeary J.E., Francazio S., Raphael B.J., Lander A.D., Heath A.C., Knopik V.S. The genetics of alcohol dependence: advancing towards systems-based approaches. Drug Alcohol Depend. 2012, 125:179-191.
113. Ron D., Messing R.O. Signaling pathways mediating alcohol effects. Current Topics Behav. Neurosci. 2013, 13:87-126.
114. Warren K.R., Hewitt B.G., Thomas J.D. Fetal alcohol spectrum disorders: research challenges and opportunities. Alcohol Res. Health 2011, 34:4-14.
115. Xiao J. International Handbook on Alcohol and Culture 1995, 42-50. China, Greenwood Press, Westport, CT. D.B. Heath (Ed.).
116. Benowitz N.L. Nicotine and postoperative management of pain. Anesth. Analg. 2008, 107:739-741.
117. de Assis Viegas C.A. Non-cigarette forms of tobacco use. Jornal Brasileiro de Pneumologia 2008, 34:1069-1073.
118. Dwyer J.B., McQuown S.C., Leslie F.M. The dynamic effects of nicotine on the developing brain. Pharmacol. Ther. 2009, 122:125-139.
119. Eissenberg T., Shihadeh A. Waterpipe tobacco and cigarette smoking: direct comparison of toxicant exposure. Am. J. Prev. Med. 2009, 37:518-523.
120. Fowler C.D., Arends M.A., Kenny P.J. Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice. Behav. Pharmacol. 2008, 19:461-484.
121. Heinz A.J., Kassel J.D., Berbaum M., Mermelstein R. Adolescents' expectancies for smoking to regulate affect predict smoking behavior and nicotine dependence over time. Drug. Alcohol. Depend. 2010, 111:128-135.
122. Herman C.P., Kozlowski L.T. Indulgence, excess, and restraint: perspectives on consummatory behavior in everyday life. J. Drug. Issues. 1979, 9:185-196.
123. Hughes J.R. Tobacco withdrawal in self-quitters. J. Consult. Clin. Psychol. 1992, 60:689-697.
124. Laviolette S.R., van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behavior. Nat. Rev. Neurosci. 2004, 5:55-65.
125. Leslie F.M. Multigenerational epigenetic effects of nicotine on lung function. BMC Medicine 2013, 27(11).
126. Maziak W. The global epidemic of waterpipe smoking. Addict. Behav. 2011, 36:1-5.
127. Noonan D., Kulbok P.A. New tobacco trends: waterpipe (hookah) smoking and implications for healthcare providers. J. Am. Acad. Nurse. Pract. 2010, 21:258-260.
128. Pearson J.L., Richardson A., Niaura R.S., Vallone D.M., Abrams D.B. e-Cigarette awareness, use, and harm perceptions in US adults. Am. J. Public. Health. 2012, 102:1758-1766.
129. Shiffman S., Paty J.A., Kassel J.D., Gnys M., Zettler-Segal M. Smoking behavior and smoking history of tobacco chippers. Exp. Clin. Psychopharmacol. 1994, 2:126-142.
130. Tucker J.S., Ellickson P.L., Klein D.J. Predictors of the transition to regular smoking during adolescence and young adulthood. J. Adolesc. Health. 2003, 32:314-324.
131. Asbridge M., Hayden J.A., Cartwright J.L. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. British Medical Journal 2012, 344:e536.
132. Bergamaschi M.M., Crippa J.A. Why should cannabis be considered doping in sports?. Frontiers in Psychiatry 2013, 4:32.
133. Fergusson D.M., Boden J.M., Horwood L.J. Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction 2006, 101:556-569.
134. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 2003, 83:1017-1066.
135. Frytak S., Moertel C.G., Rubin J. Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients. Cancer Treatment Reports 1984, 68:1427-1431.
136. Haney M., Bisaga A., Foltin R.W. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology 2003, 166:77-85.
137. Hirvonen J., Goodwin R.S., Li C.T., Terry G.E., Zoghbi S.S., Morse C., Pike V.W., Volkow N.D., Huestis M.A., Innis R.B. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol. Psychiatry. 2012, 17:642-649.
138. Huestis M.A., Henningfield J.E., Cone E.J. Blood cannabinoids: I: Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J. Analyt. Toxicol. 1992, 16:276-282.
139. Kandel D.B. Stages in adolescent involvement in drug use. Science 1975, 190:912-914.
140. Li H.L. An archaeological and historical account of cannabis in China. Economic Botany 1974, 28:437-448.
141. Li H.L. The origin and use of cannabis in Eastern Asia: linguistic-cultural implications. Economic Botany 1974, 28:293-301.
142. McGlothlin W.H., West L.J. The marihuana problem: an overview. Am. J. Psychiatry. 1968, 125:126-134.
143. McGrath J., Welham J., Scott J., Varghese D., Degenhardt L., Hayatbakhsh M.R., Alati R., Williams G.M., Bor W., Najman J.M. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch. Gen. Psychiatry. 2010, 67:440-447.
144. Musshoff F., Madea B., Kernbach-Wighton G., Bicker W., Kneisel S., Hutter M., Auwärter V. Driving under the influence of synthetic cannabinoids ("Spice"): a case series. Int. J. Legal. Med. 2013, 128:59-64.
145. Ohlsson A., Lindgren J.E., Wahlen A., Agurell S., Hollister L.E., Gillespie H.K. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin. Pharmacol. Therapeut. 1980, 28:409-416.
146. Seely K.A., Lapoint J., Moran J.H., Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012, 39:234-243.
147. Stott C.G., White L., Wright S., Wilbraham D., Guy G.W. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur. J. Clin. Pharmacol. 2013, 69:1135-1147.
148. Timpone J.G., Wright D.J., Li N., Egorin M.J., Enama M.E., Mayers J., Galetto G. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses 1997, 13:305-315.
149. Ameisen O. The end of my addiction: le dernier verre (the last glass). Sarah Crichton Books, New York.
150. Blomeyer D., Treutlein J., Esser G., Schmidt M.H., Schumann G., Laucht M. Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use. Biol. Psychiatry 2008, 63:146-151.
151. Brimijoin S., Shen X., Orson F., Kosten T. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev. Vaccines 2013, 12:323-332.
152. Cowan A. Buprenorphine: the basic pharmacology revisited. J. Addict. Med. 2007, 1:68-72.
153. Fowler J.S., Volkow N.D., Kassed C.A., Chang L. Imaging the addicted human brain. Sci. Pract. Perspect. 2007, 3:4-16.
154. Heilig M., Goldman D., Berrettini W., O'Brien C.P. Pharmacogenetic approaches to the treatment of alcohol addiction. Nat. Rev. Neurosci. 2011, 12:670-684.
155. Koob G.F. New dimensions in human laboratory models of addiction. Addict. Biol. 2009, 14:1-8.
156. Koob G.F., Everitt B.J., Robbins T.W. Reward, motivation, and addiction. Fundamental Neuroscience 2008, 987-1016. Amsterdam, Academic Press. 3rd edition. L.R. Squire, D. Berg, F.E. Bloom, S. du Lac, A. Ghosh, N.C. Spitzer (Eds.).
157. Koob G.F., Lloyd G.K., Mason B.J. Development of pharmacotherapies for drug addiction: a Rosetta Stone approach. Nat. Rev. Drug Discov. 2009, 8:500-515.
158. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacol. Rev. 2010, 35:217-238. [erratum: (35), 1051].
159. Koob G.F., Zorrilla E.P. Update on corticotropin-releasing factor pharmacotherapy for psychiatric disorders: a revisionist view. Neuropsychopharmacol. Rev. 2012, 37:308-309.
160. Littleton J.M. Acamprosate in alcohol dependence: implications of a unique mechanism of action. J. Addict. Med. 2007, 1:115-125.
161. Mason B.J., Crean R., Goodell V., Light J.M., Quello S., Shadan F., Buffkins K., Kyle M., Adusumalli M., Begovic A., Rao S. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012, 37:1689-1698.
162. Mason B.J., Light J.M., Williams L.D., Drobes D.J. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict. Biol. 2009, 14:73-83.
163. Mason B.J., Quello S., Goodell V., Shaden F., Kyle M., Begovic A. Gabapentin treatment for alcohol dependence: a randomized controlled trial. JAMA Intern. Med. 2014, 174:70-77.
164. McKee S.A. Developing human laboratory models of smoking lapse behavior for medication screening. Addict. Biol. 2009, 14:99-107.
165. Moreno A.Y., Janda K.D. Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol. Biochem. Behav. 2009, 92:199-205.
166. Steensland P., Fredriksson I., Holst S., Feltmann K., Franck J., Schilström B., Carlsson A. The monoamine stabilizer (-)-OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens. Biol. Psychiatry 2012, 72:823-831.
167. Unterwald E.M. Naltrexone in the treatment of alcohol dependence. J. Addict. Med. 2008, 2:121-127.
168. Wee S., Koob G.F. The role of the dynorphin-κ opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology 2010, 210:121-135.
169. Wolf M.E. The Bermuda Triangle of cocaine-induced neuroadaptations. Trends Neurosci. 2010, 33:391-398.